Delta-Fly Pharma Inc.: Update on the Interim Analysis Status of Phase III Study of DFP-10917 in the patients with R/R AML
TOKUSHIMA, Japan--(BUSINESS WIRE)--Following the previous information on Jan. 5th. in 2024, we are excited to share our latest development status....




















